ATE414690T1 - Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten - Google Patents
Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonistenInfo
- Publication number
- ATE414690T1 ATE414690T1 AT03700740T AT03700740T ATE414690T1 AT E414690 T1 ATE414690 T1 AT E414690T1 AT 03700740 T AT03700740 T AT 03700740T AT 03700740 T AT03700740 T AT 03700740T AT E414690 T1 ATE414690 T1 AT E414690T1
- Authority
- AT
- Austria
- Prior art keywords
- cycloalkanindoles
- prostaglandin
- fluoro
- substituted
- receptor antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35138402P | 2002-01-24 | 2002-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE414690T1 true ATE414690T1 (de) | 2008-12-15 |
Family
ID=27613492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03700740T ATE414690T1 (de) | 2002-01-24 | 2003-01-22 | Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US20030158246A1 (de) |
| EP (3) | EP2295409B1 (de) |
| JP (2) | JP4008885B2 (de) |
| KR (2) | KR100859230B1 (de) |
| CN (3) | CN101851191A (de) |
| AR (1) | AR038136A1 (de) |
| AT (1) | ATE414690T1 (de) |
| AU (1) | AU2003202343B2 (de) |
| BR (1) | BR0307050A (de) |
| CA (1) | CA2471952C (de) |
| CY (3) | CY1108841T1 (de) |
| DE (2) | DE60324767D1 (de) |
| DK (2) | DK1470107T3 (de) |
| DO (1) | DOP2003000566A (de) |
| EA (1) | EA006134B1 (de) |
| EC (1) | ECSP045203A (de) |
| EG (1) | EG24978A (de) |
| ES (2) | ES2391747T3 (de) |
| FR (1) | FR09C0010I2 (de) |
| GE (1) | GEP20074078B (de) |
| HR (1) | HRP20040665B1 (de) |
| IL (3) | IL162825A0 (de) |
| IS (2) | IS2633B (de) |
| JO (1) | JO2481B1 (de) |
| LU (1) | LU91534I2 (de) |
| MX (1) | MXPA04007167A (de) |
| MY (1) | MY137040A (de) |
| NL (1) | NL300377I2 (de) |
| NO (3) | NO327322B1 (de) |
| NZ (1) | NZ533786A (de) |
| PE (1) | PE20030982A1 (de) |
| PL (1) | PL208527B1 (de) |
| PT (2) | PT2045241E (de) |
| RS (2) | RS20100338A (de) |
| SI (2) | SI1470107T1 (de) |
| TW (1) | TWI259080B (de) |
| UA (1) | UA75520C2 (de) |
| WO (1) | WO2003062200A2 (de) |
| ZA (1) | ZA200404999B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217725B2 (en) * | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| WO2004104205A2 (en) * | 2003-05-16 | 2004-12-02 | Merck & Co., Inc. | Enzymatic preparation of chiral indole esters |
| CN1791577A (zh) * | 2003-05-20 | 2006-06-21 | 麦克弗罗斯特加拿大有限公司 | 氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途 |
| WO2005013985A1 (en) * | 2003-08-07 | 2005-02-17 | Merck Sharp & Dohme Limited | Treatment for alzheimer's disease and related conditions |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| BRPI0508540B8 (pt) | 2004-03-11 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| ATE384046T1 (de) * | 2004-04-02 | 2008-02-15 | Merck & Co Inc | Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| US20070299122A1 (en) * | 2004-11-08 | 2007-12-27 | Tobert Jonathan A | Method of Treating Pathological Blushing |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| JPWO2006068162A1 (ja) * | 2004-12-24 | 2008-06-12 | 塩野義製薬株式会社 | 慢性閉塞性肺疾患の治療剤 |
| PL1833791T3 (pl) | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
| US20080139604A1 (en) * | 2005-02-17 | 2008-06-12 | Shaun Fitzpatrick | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| CA2603757A1 (en) * | 2005-04-13 | 2006-10-26 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| EP1911759A4 (de) | 2005-07-22 | 2010-07-21 | Shionogi & Co | Azaindolderivat mit antagonistischer wirkung am pgd2-rezeptor |
| EP2397476A3 (de) | 2005-07-22 | 2011-12-28 | Shionogi & Co., Ltd. | Indolderivat mit PGD2-Rezeptor-Antagonist-Aktivität |
| JP5147401B2 (ja) | 2005-09-06 | 2013-02-20 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| PL2037967T3 (pl) | 2006-06-16 | 2017-07-31 | The Trustees Of The University Of Pennsylvania | Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego |
| JP5220013B2 (ja) | 2006-08-07 | 2013-06-26 | アクテリオン ファーマシューティカルズ リミテッド | （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体 |
| US20100260841A1 (en) * | 2007-02-08 | 2010-10-14 | Paolini John F | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20090076117A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched laropiprant |
| WO2010008864A2 (en) | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| US8507473B2 (en) | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
| CN102224154A (zh) * | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US9180114B2 (en) * | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| US8882678B2 (en) * | 2009-03-13 | 2014-11-11 | Atrium Medical Corporation | Pleural drainage system and method of use |
| MA34094B1 (fr) | 2010-03-22 | 2013-03-05 | Actelion Pharmaceuticals Ltd | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 |
| MX338516B (es) | 2011-04-14 | 2016-04-20 | Actelion Pharmaceuticals Ltd | Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina. |
| JP5841361B2 (ja) * | 2011-06-29 | 2016-01-13 | 壽製薬株式会社 | 三環性化合物及びそれを含有する医薬組成物 |
| AR088377A1 (es) * | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102659664B (zh) * | 2012-03-28 | 2015-01-21 | 中国计量学院 | 合成分离拉洛皮兰及其类似物的方法 |
| FR3000395A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee |
| FR3000399B1 (fr) * | 2012-12-31 | 2015-03-27 | Galderma Res & Dev | Utilisation topique du laropiprant pour le traitement de la rosacee |
| MY179356A (en) | 2014-03-17 | 2020-11-05 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| EP3119780B1 (de) | 2014-03-18 | 2018-08-29 | Idorsia Pharmaceuticals Ltd | Azaindolessigsäurederivate und deren verwendung als prostaglandin-d2-rezeptormodulatoren |
| US20180021302A1 (en) | 2015-02-13 | 2018-01-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| MX2018003202A (es) | 2015-09-15 | 2018-06-08 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| KR102465211B1 (ko) | 2018-03-19 | 2022-11-10 | 미쯔이가가꾸가부시끼가이샤 | 표시 소자용 밀봉재 및 그의 경화물, 유기 el 소자용 프레임 밀봉재, 그리고 유기 el 소자용 면 밀봉재 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535326A (en) * | 1967-03-06 | 1970-10-20 | Sumitomo Chemical Co | Certain tetrahydro carboline derivatives |
| BE787444A (fr) * | 1971-08-13 | 1973-02-12 | Hoffmann La Roche | Composes polycycliques |
| US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3768097D1 (de) | 1986-01-23 | 1991-04-04 | Merck Frosst Canada Inc | Tetrahydrocarbazol-1-alkansaeuren. |
| US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
| US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| US4940719A (en) * | 1986-03-27 | 1990-07-10 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole esters, pharmaceutical compositions and use |
| US4775680A (en) * | 1987-07-21 | 1988-10-04 | Merck & Co., Inc. | Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use |
| US5221678A (en) | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| GB9101375D0 (en) | 1991-01-22 | 1991-03-06 | Erba Carlo Spa | N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole |
| WO1995015973A1 (en) | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| DE69530392D1 (de) | 1994-07-11 | 2003-05-22 | Athena Neurosciences Inc | Inhibitoren der leukozytenadhäsion |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
| MX9710256A (es) | 1995-06-21 | 1998-03-31 | Shionogi & Co | Derivados de amino biciclicos y antagonistas pgd2 que contienen los mismos. |
| AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| ES2181039T3 (es) | 1996-12-13 | 2003-02-16 | Shionogi & Co | Derivados de benzotiofenocarboxamida y antagonistas de pgd2 que los comprenden. |
| CN1198649C (zh) | 1998-06-03 | 2005-04-27 | 盐野义制药株式会社 | 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物 |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
-
2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/de not_active Expired - Lifetime
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/en unknown
- 2003-01-22 RS YU62404A patent/RS51672B/en unknown
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active IP Right Cessation
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en active Application Filing
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Application Discontinuation
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 EP EP08105552A patent/EP2045241B1/de not_active Expired - Lifetime
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 EP EP03700740A patent/EP1470107B1/de not_active Expired - Lifetime
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
-
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-19 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
-
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
-
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
-
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
-
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
-
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
-
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE414690T1 (de) | Fluoro substituierte cycloalkanindole und deren verwendung als prostaglandin d2 rezeptor antagonisten | |
| DE602005023639D1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
| ATE446953T1 (de) | P2x7-rezeptorantagonisten und deren verwendung | |
| ATE409182T1 (de) | Tetrahydrochinolinone und deren verwendung als antagonisten von metabotropen glutamatrezeptoren | |
| ATE346056T1 (de) | Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren | |
| ATE378338T1 (de) | Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten | |
| ATE489369T1 (de) | Pyrimidinderivate und deren verwendung als cb2- modulatoren | |
| DE60321043D1 (de) | Biphenylderivate und deren verwendung als fungizide | |
| ATE435872T1 (de) | Anti-interleukin-1 rezeptor antikörper und deren verwendung | |
| ATE396185T1 (de) | Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
| ATE456581T1 (de) | Antikörper gegen il21-rezeptor und deren verwendung | |
| ATE500242T1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten | |
| DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
| ATE418543T1 (de) | Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten | |
| DE60114413D1 (de) | Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten | |
| ATE511507T1 (de) | Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten | |
| FI20060188A (fi) | Modifioidut IL-4-muteiinin reseptorin antagonistit | |
| DE602004022458D1 (de) | Pyrazolderivate und ihre verwendung als orexin-rezeptor-antagonisten | |
| DE60320457D1 (de) | Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors | |
| DE60317632D1 (de) | 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten | |
| ATE372342T1 (de) | Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva | |
| DE60215217D1 (de) | Substituierte arylcycloalkane und deren verwendung als antikrebsmittel | |
| DE602004021949D1 (de) | Anti-interleukin-1 rezeptor antikörper und deren verwendung |